Categories AlphaGraphs, Earnings, Industrials

AngioDynamics second-quarter results beat market estimates

AngioDynamics posted second-quarter earnings on Friday, Jan. 4. before trading hours. Net sales for the period inched 5.5% to $91.5 million, with diluted net profit jumping to $0.06 per share — growing six-fold from last year’s $0.01 per share. Net income soared to $2.14 million, up from $249,000.

The market expected earnings of $0.20 per share on revenue of $88.90 million. Both top line and bottom line exceeded the consensus.

Gross margin for the quarter soared 440 basis points year over year to 53.7%, while cash provided by operations was $13.0 million. Capital expenditures was $0.7 million for the period.

US net sales in the quarter rose 5.2% to $71.9 million while International net sales grow 6.6% to $19.6 million.

AngioDynamics second quarter 2019 Earnings Infographic

Back in September, AngioDynamics announced that it would acquire privately held medical diagnostic and device company RadiaDyne. The latter designs and develops patient dose monitoring technology to improve cancer treatment outcomes.

This deal added to AngioDynamics’ portfolio RadiaDyne’s early-stage, proprietary real-time radiation dose monitoring platform and other market-leading oncology solutions.

“The acquisition of RadiaDyne, combined with our recent BioSentry asset purchase, delivers on our commitment to build a world-class oncology portfolio,” said CEO Jim Clemmer.

In September of 2018, RadiaDyne’s trailing 12-months revenues exceeded $6 million. The acquisition was then expected to be neutral to earnings on an adjusted basis.

In the previously reported first-quarter, AngioDynamics missed analyst estimates with earnings of $0.16 per share, sending shares down then. The company had reported flat revenues of $85.3 million over last year, hurt by 6% slump in oncology product sales. it also had a one-time impact in the quarter due to its transition from Acculis to Solero product line.

Also Read:  Microsoft wins US Army contract to supply HoloLens

AngioDynamics has been seeing US sales dipping in the past two quarters, despite international sales picking up. Last quarter, it even had to pay $12.7 million due to the legal allegations faced with the Justice Department.

 

 

We’re on Flipboard! Follow us to receive the latest stock market, earnings, and financial news at your fingertips

Most Popular

Southwest is looking northside as lockdown restrictions ease

When Warren Buffett dumped airline stocks suffering massive losses three weeks ago, he probably overlooked one key aspect about the industry – that no amount of restrictions will kill people’s

Alibaba (BABA) entering a new phase as China emerges from COVID crisis

Alibaba Group Holding Ltd (NYSE: BABA) is striving to regain strength after falling sharply last week, ahead of fourth-quarter earnings. The positive results failed to impress stakeholders as market sentiment

Chinese exodus from US exchanges not an unlikely scenario

The US is now back in the ring with its nemesis China for the second round. This time, the US administration has wasted no time in delivering a massive blow,

Top